TEM-2
Oncology (Undisclosed)
Key Facts
About Tempus AI
Tempus AI is a public technology company with a mission to enable data-driven, personalized medicine through its proprietary AI platform and massive, structured real-world data library. Its core strategy involves a virtuous cycle: generating revenue through clinical testing and data/analytics services for providers and life sciences companies, while using that same data flow to fuel internal therapeutic discovery and enhance its platform's predictive power. Key achievements include establishing a dominant data network with over 65% of U.S. academic medical centers, securing multiple FDA clearances for its diagnostic assays, building a pipeline of seven internal drug candidates, and being selected for strategic government partnerships like the ARPA-H ADAPT program.
View full company profileTherapeutic Areas
Other Oncology (Undisclosed) Drugs
| Drug | Company | Phase |
|---|---|---|
| CLD-601 | Calidi Biotherapeutics | Discovery |
| Protease Inhibitor Discovery Programs | Medivir | Discovery |
| Nucleoside/Nucleotide Discovery Programs | Medivir | Discovery |
| Orion Collaboration Program 1 | Glykos Finland | Research/Preclinical |
| Orion Collaboration Program 2 | Glykos Finland | Research/Preclinical |
| Orion Collaboration Program 3 | Glykos Finland | Research/Preclinical |
| Orion Collaboration Program 4-6 (Extended) | Glykos Finland | Research |
| ISB 830 | Glenmark Pharmaceuticals | Preclinical |
| TEM-1 | Tempus AI | Discovery/Preclinical |
| TEM-3 | Tempus AI | Discovery/Preclinical |
| TEM-4 | Tempus AI | Discovery/Preclinical |
| TEM-5 | Tempus AI | Discovery/Preclinical |